EUDA vs. PSNL, AIRS, VMD, LFMD, SERA, BDSX, QIPT, XGN, TOI, and PIII
Should you be buying EUDA Health stock or one of its competitors? The main competitors of EUDA Health include Personalis (PSNL), AirSculpt Technologies (AIRS), Viemed Healthcare (VMD), LifeMD (LFMD), Sera Prognostics (SERA), Biodesix (BDSX), Quipt Home Medical (QIPT), Exagen (XGN), Oncology Institute (TOI), and P3 Health Partners (PIII). These companies are all part of the "healthcare" industry.
EUDA Health vs.
EUDA Health (NASDAQ:EUDA) and Personalis (NASDAQ:PSNL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.
Personalis received 120 more outperform votes than EUDA Health when rated by MarketBeat users. However, 100.00% of users gave EUDA Health an outperform vote while only 67.60% of users gave Personalis an outperform vote.
EUDA Health has a net margin of 0.00% compared to Personalis' net margin of -104.52%. EUDA Health's return on equity of 0.00% beat Personalis' return on equity.
Personalis has a consensus target price of $7.81, indicating a potential upside of 65.52%. Given Personalis' higher probable upside, analysts plainly believe Personalis is more favorable than EUDA Health.
In the previous week, EUDA Health had 1 more articles in the media than Personalis. MarketBeat recorded 3 mentions for EUDA Health and 2 mentions for Personalis. Personalis' average media sentiment score of 0.37 beat EUDA Health's score of 0.26 indicating that Personalis is being referred to more favorably in the news media.
4.4% of EUDA Health shares are owned by institutional investors. Comparatively, 61.9% of Personalis shares are owned by institutional investors. 4.1% of Personalis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
EUDA Health has higher earnings, but lower revenue than Personalis.
EUDA Health has a beta of -0.04, indicating that its stock price is 104% less volatile than the S&P 500. Comparatively, Personalis has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500.
Summary
EUDA Health beats Personalis on 9 of the 17 factors compared between the two stocks.
Get EUDA Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for EUDA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
EUDA Health Competitors List
Related Companies and Tools
This page (NASDAQ:EUDA) was last updated on 2/22/2025 by MarketBeat.com Staff
Free EUDA Stock Alerts